EA033457B1 - Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3 - Google Patents

Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3

Info

Publication number
EA033457B1
EA033457B1 EA201691151A EA201691151A EA033457B1 EA 033457 B1 EA033457 B1 EA 033457B1 EA 201691151 A EA201691151 A EA 201691151A EA 201691151 A EA201691151 A EA 201691151A EA 033457 B1 EA033457 B1 EA 033457B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
ntrk2
ntrk1
ros1
patient
Prior art date
Application number
EA201691151A
Other languages
English (en)
Other versions
EA201691151A1 (ru
Inventor
Jonathan Lim
Elena Ardini
Maria Menichincheri
Original Assignee
Ignyta Inc
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc, Nerviano Medical Sciences Srl filed Critical Ignyta Inc
Publication of EA201691151A1 publication Critical patent/EA201691151A1/ru
Publication of EA033457B1 publication Critical patent/EA033457B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложен способ лечения рака у пациента, где указанный пациент имеет по меньшей мере одно генетическое изменение по меньшей мере в одном целевом гене, выбранном из ROS1, NTRK1, NTRK2 и NTRK3, включающий введение указанному пациенту терапевтически эффективного количества N-[5-(3,5-дифторбензил)-1H-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидро-2H-пиран-4-иламино)бензамида или его фармацевтически приемлемой соли. Согласно предпочтительным вариантам реализации указанный рак выбран из немелкоклеточного рака легких, папиллярного рака щитовидной железы, нейробластомы, рака поджелудочной железы и колоректального рака.
EA201691151A 2014-02-20 2015-02-19 Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3 EA033457B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461942287P 2014-02-20 2014-02-20
US201462052994P 2014-09-19 2014-09-19
US201462055450P 2014-09-25 2014-09-25
US201462069999P 2014-10-29 2014-10-29
PCT/EP2015/053544 WO2015124697A1 (en) 2014-02-20 2015-02-19 Compounds for treating patients with ros1 mutant cancer cells

Publications (2)

Publication Number Publication Date
EA201691151A1 EA201691151A1 (ru) 2017-01-30
EA033457B1 true EA033457B1 (ru) 2019-10-31

Family

ID=52544499

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691151A EA033457B1 (ru) 2014-02-20 2015-02-19 Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3

Country Status (20)

Country Link
US (4) US10231965B2 (ru)
EP (2) EP3834827A1 (ru)
JP (1) JP6636933B2 (ru)
KR (2) KR20160117611A (ru)
CN (1) CN106029073A (ru)
AU (1) AU2015220832B2 (ru)
BR (1) BR112016015818A2 (ru)
CA (1) CA2933623C (ru)
CL (1) CL2016001507A1 (ru)
EA (1) EA033457B1 (ru)
ES (1) ES2856231T3 (ru)
IL (1) IL246544B (ru)
MX (1) MX2016010519A (ru)
NL (1) NL301111I2 (ru)
PH (1) PH12016501394A1 (ru)
PL (1) PL3107541T3 (ru)
SG (1) SG11201605816TA (ru)
TW (1) TWI672141B (ru)
UA (1) UA118773C2 (ru)
WO (1) WO2015124697A1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
SI3372605T1 (sl) 2008-10-22 2022-03-31 Array Biopharma, Inc. Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP3521291A1 (en) 2010-05-20 2019-08-07 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
DK2960234T3 (en) 2013-02-19 2019-04-01 Ono Pharmaceutical Co TRK-INHIBITING CONNECTION
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
MX2017006412A (es) 2014-11-16 2017-09-12 Array Biopharma Inc Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida.
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ，インコーポレイテッド 神経芽細胞腫の治療のための併用
EP3227686A4 (en) * 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
MA44936A1 (fr) 2015-06-01 2021-09-30 Loxo Oncology Inc Méthodes de diagnostic et de traitement du cancer
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
AU2016370846B2 (en) * 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
MX2018012163A (es) 2016-04-04 2019-07-08 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirr olidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina- 1-carboxamida.
KR20180129911A (ko) 2016-04-04 2018-12-05 록쏘 온콜로지, 인코포레이티드 소아암을 치료하는 방법
RS61463B1 (sr) 2016-05-18 2021-03-31 Loxo Oncology Inc Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
BR112018073951A2 (pt) * 2016-05-24 2019-02-26 Nerviano Medical Sciences Srl forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
JP2019527231A (ja) * 2016-08-01 2019-09-26 イグナイタ インコーポレイテッド がんを治療するための組み合わせ
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20200031115A (ko) 2017-07-19 2020-03-23 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074749A1 (en) * 2006-12-20 2008-06-26 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
WO2009013126A1 (en) * 2007-07-20 2009-01-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2013119950A2 (en) * 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
WO2013174876A1 (en) * 2012-05-23 2013-11-28 Nerviano Medical Sciences S.R.L. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
AU2882699A (en) 1998-02-27 1999-09-15 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
DE60215682T2 (de) 2001-09-27 2007-09-06 Smithkline Beecham Corp. AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
AU2002353186A1 (en) 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003251875A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
CA2497351C (fr) 2002-09-05 2012-08-21 Aventis Pharma S.A. Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
KR20050084271A (ko) 2002-12-12 2005-08-26 아방티 파르마 소시에테 아노님 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
ES2371383T3 (es) 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
CA2544074A1 (en) 2003-10-24 2005-05-06 Esbatech Ag Method for the identification and/or validation of receptor tyrosine kinase inhibitors
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7605272B2 (en) 2005-01-27 2009-10-20 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
JP2009504608A (ja) 2005-08-09 2009-02-05 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ 薬剤耐性肺癌のタンパク質キナーゼ阻害剤への感作
WO2007075847A2 (en) 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
ES2493566T3 (es) 2006-07-07 2014-09-12 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
BRPI0722384A2 (pt) 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
AU2007333536A1 (en) 2006-12-11 2008-06-19 Irm Llc Compounds and compositions as kinase inhibitors
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
BRPI0816064B8 (pt) 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
SI3372605T1 (sl) 2008-10-22 2022-03-31 Array Biopharma, Inc. Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
AU2013229173B2 (en) 2012-03-06 2017-06-01 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
BR112015006537A2 (pt) 2012-09-28 2017-07-04 Oncoethix Sa dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
DE102013012850A1 (de) * 2013-08-02 2015-02-05 Sew-Eurodrive Gmbh & Co Kg Elektromotor mit Rotorwelle und Gehäuseteil
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
PT3154959T (pt) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
WO2015184443A1 (en) * 2014-05-30 2015-12-03 The Regents Of The University Of Colorado Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
JP2017517579A (ja) 2014-06-13 2017-06-29 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる非小細胞肺癌及び／又は小細胞肺癌の治療方法
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ，インコーポレイテッド 神経芽細胞腫の治療のための併用
EP3227686A4 (en) 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
CA2987281A1 (en) 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
MA44936A1 (fr) 2015-06-01 2021-09-30 Loxo Oncology Inc Méthodes de diagnostic et de traitement du cancer
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
KR20200031115A (ko) 2017-07-19 2020-03-23 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074749A1 (en) * 2006-12-20 2008-06-26 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
WO2009013126A1 (en) * 2007-07-20 2009-01-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2013119950A2 (en) * 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
WO2013174876A1 (en) * 2012-05-23 2013-11-28 Nerviano Medical Sciences S.R.L. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. GRECO, C. MIRANDA, M.A. PIEROTTI: "Rearrangements of NTRK1 gene in papillary thyroid carcinoma", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 321, no. 1, 1 May 2010 (2010-05-01), pages 44 - 49, XP055176824, ISSN: 03037207, DOI: 10.1016/j.mce.2009.10.009 *
LIPSKA BEATA S; DROŻYNSKA ELŻBIETA; SCARUFFI PAOLA; TONINI GIAN PAOLO; IŻYCKA-ŚWIESZEWSKA EWA; ZIĘTKIEWICZ SZYMON; BALCERSKA ANNA;: "c.1810C>T Polymorphism of NTRK1 Gene is associated with reduced Survival in Neuroblastoma Patients", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 13 December 2009 (2009-12-13), LONDON, GB, pages 436, XP021067003, ISSN: 1471-2407, DOI: 10.1186/1471-2407-9-436 *

Also Published As

Publication number Publication date
CN106029073A (zh) 2016-10-12
JP2017506255A (ja) 2017-03-02
SG11201605816TA (en) 2016-08-30
NL301111I1 (ru) 2021-06-23
EP3834827A1 (en) 2021-06-16
IL246544B (en) 2019-12-31
CA2933623A1 (en) 2015-08-27
PH12016501394A1 (en) 2017-02-20
US20190282564A1 (en) 2019-09-19
AU2015220832A2 (en) 2016-09-08
US20150283132A1 (en) 2015-10-08
TWI672141B (zh) 2019-09-21
US20180333412A1 (en) 2018-11-22
KR20220165787A (ko) 2022-12-15
US10231965B2 (en) 2019-03-19
EP3107541B1 (en) 2020-12-23
IL246544A0 (en) 2016-08-31
CA2933623C (en) 2022-05-17
AU2015220832A1 (en) 2016-09-08
BR112016015818A2 (pt) 2017-08-08
KR102634514B1 (ko) 2024-02-07
PL3107541T3 (pl) 2021-09-20
US20170007599A1 (en) 2017-01-12
KR20160117611A (ko) 2016-10-10
NZ722405A (en) 2021-03-26
MX2016010519A (es) 2016-11-16
UA118773C2 (uk) 2019-03-11
US10682348B2 (en) 2020-06-16
TW201613593A (en) 2016-04-16
EP3107541A1 (en) 2016-12-28
WO2015124697A1 (en) 2015-08-27
EA201691151A1 (ru) 2017-01-30
AU2015220832B2 (en) 2020-02-27
US10561651B2 (en) 2020-02-18
NL301111I2 (nl) 2021-09-27
JP6636933B2 (ja) 2020-01-29
CL2016001507A1 (es) 2017-02-10
ES2856231T3 (es) 2021-09-27

Similar Documents

Publication Publication Date Title
EA033457B1 (ru) Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3
JOP20210207A1 (ar) مركبات ترابطية مستهدفة
MX2023006332A (es) Ligandos dirigidos para compuestos terapeuticos.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
WO2018154462A3 (en) Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
PH12018500088A1 (en) Substituted tricyclics and method of use
NZ745957A (en) Heterocyclic amides useful as protein modulators
WO2016176690A3 (en) Gene therapy for autosomal dominant diseases
BR112018012894A2 (pt) materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
MX2018005332A (es) Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
FI3618875T3 (fi) Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
MX2018004309A (es) Terapias combinadas para tratar el cancer.
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2021012511A (es) Delecion mediada por vector aav de punto activo mutacional grande para el tratamiento de distrofia muscular de duchenne.
MX2021000127A (es) Formulaciones de un inhibidor de axl/mer.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
SG10201907746TA (en) Methods of treating cancer harboring hemizygous loss of tp53
NZ745329A (en) Gene therapy for the treatment of a disease of retinal cone cells

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM